Drug General Information |
Drug ID |
D04FHB
|
Former ID |
DCL001079
|
Drug Name |
R547
|
Synonyms |
LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone
|
Drug Type |
Small molecular drug
|
Indication |
Advanced solid tumor [ICD9: 140-199; ICD10:C00-C75, C7A, C7B]
|
Discontinued in Phase 1 |
[1],
[2]
|
Company |
Hoffmann CLa Roche
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H21F2N5O4S
|
InChI |
InChI=1S/C18H21F2N5O4S/c1-29-13-4-3-12(19)15(20)14(13)16(26)11-9-22-18(24-17(11)21)23-10-5-7-25(8-6-10)30(2,27)28/h3-4,9-10H,5-8H2,1-2H3,(H3,21,22,23,24)
|
InChIKey |
JRNJNYBQQYBCLE-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
12015951, 15453136, 17195139, 17403967, 43530215, 46394148, 46513075, 50076906, 52508604, 57372039, 99444565, 103501363, 114788663, 126635301, 126671462, 136349555, 136367686, 136920370, 137220536, 139479662, 152258059, 160646897, 160969149, 162011616, 162142463, 162205203, 163642576, 164777773, 171578722, 174007020, 174530544, 178102334, 180404375, 186014498, 189622859, 196109935, 198942799, 223401007, 223680327, 223704837, 223892540, 228511370, 241140956, 242586092, 248485759, 251971023, 252160625, 252216168, 252438943, 252671609
|
Target and Pathway |
Target(s) |
Cell division protein kinase 4 |
Target Info |
Inhibitor |
[3]
|
Cell division control protein 2 homolog |
Target Info |
Inhibitor |
[3]
|
Cell division protein kinase 7 |
Target Info |
Inhibitor |
[3]
|
Cell division protein kinase 2 |
Target Info |
Inhibitor |
[3]
|
KEGG Pathway
|
Cell cycle
|
p53 signaling pathway
|
PI3K-Akt signaling pathway
|
Tight junction
|
T cell receptor signaling pathway
|
Hepatitis B
|
Measles
|
HTLV-I infection
|
Pathways in cancer
|
Viral carcinogenesis
|
Pancreatic cancer
|
Glioma
|
Melanoma
|
Bladder cancer
|
Chronic myeloid leukemia
|
Small cell lung cancer
|
Non-small cell lung cancerhsa04110:Cell cycle
|
Oocyte meiosis
|
Gap junction
|
Progesterone-mediated oocyte maturation
|
Herpes simplex infection
|
Epstein-Barr virus infection
|
Viral carcinogenesishsa03022:Basal transcription factors
|
Nucleotide excision repair
|
Cell cyclehsa04068:FoxO signaling pathway
|
Prostate cancer
|
NetPath Pathway
|
TCR Signaling Pathway
|
EGFR1 Signaling Pathway
|
RANKL Signaling PathwayNetPath_21:RANKL Signaling PathwayNetPath_11:TCR Signaling Pathway
|
RANKL Signaling PathwayNetPath_11:TCR Signaling Pathway
|
PANTHER Pathway
|
p53 pathway
|
p53 pathway feedback loops 2
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
Validated targets of C-MYC transcriptional activation
|
ATF-2 transcription factor network
|
FOXM1 transcription factor network
|
Regulation of retinoblastoma proteinp73pathway:p73 transcription factor network
|
E2F transcription factor network
|
PLK1 signaling events
|
AP-1 transcription factor network
|
Retinoic acid receptors-mediated signalingretinoic_acid_pathway:Retinoic acid receptors-mediated signalingsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by PRL
|
p73 transcription factor network
|
ATR signaling pathway
|
mTOR signaling pathway
|
IL2-mediated signaling events
|
FoxO family signaling
|
BARD1 signaling events
|
p53 pathway
|
Regulation of retinoblastoma protein
|
Reactome
|
Oxidative Stress Induced Senescence
|
Senescence-Associated Secretory Phenotype (SASP)
|
Oncogene Induced Senescence
|
RMTs methylate histone arginines
|
Transcriptional regulation of white adipocyte differentiation
|
Ubiquitin-dependent degradation of Cyclin D1
|
Cyclin D associated events in G1
|
Meiotic recombinationR-HSA-110056:MAPK3 (ERK1) activation
|
E2F mediated regulation of DNA replication
|
G0 and Early G1
|
Cyclin B2 mediated events
|
Golgi Cisternae Pericentriolar Stack Reorganization
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
Regulation of APC/C activators between G1/S and early anaphase
|
Phosphorylation of the APC/C
|
Phosphorylation of Emi1
|
Condensation of Prophase Chromosomes
|
MASTL Facilitates Mitotic Progression
|
Resolution of Sister Chromatid Cohesion
|
Condensation of Prometaphase Chromosomes
|
Regulation of PLK1 Activity at G2/M Transition
|
Activation of NIMA Kinases NEK9, NEK6, NEK7
|
Loss of Nlp from mitotic centrosomes
|
Recruitment of mitotic centrosome proteins and complexes
|
Loss of proteins required for interphase microtubule organization?from the centrosome
|
Recruitment of NuMA to mitotic centrosomes
|
Depolymerisation of the Nuclear Lamina
|
Anchoring of the basal body to the plasma membrane
|
MAPK6/MAPK4 signaling
|
G1/S-Specific Transcription
|
Cyclin A/B1 associated events during G2/M transition
|
G2/M DNA replication checkpoint
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-427413:NoRC negatively regulates rRNA expression
|
Formation of TC-NER Pre-Incision Complex
|
Dual incision in TC-NER
|
Gap-filling DNA repair synthesis and ligation in TC-NER
|
Cyclin E associated events during G1/S transition
|
Cyclin A:Cdk2-associated events at S phase entry
|
RNA Polymerase I Transcription InitiationR-HSA-1538133:G0 and Early G1
|
Activation of ATR in response to replication stress
|
SCF(Skp2)-mediated degradation of p27/p21
|
DNA Damage/Telomere Stress Induced Senescence
|
Processing of DNA double-strand break ends
|
G2 Phase
|
Orc1 removal from chromatin
|
p53-Dependent G1 DNA Damage Response
|
Meiotic recombination
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
DNA Damage Response
|
G1 to S cell cycle control
|
Ovarian Infertility Genes
|
PPAR Alpha Pathway
|
Bladder Cancer
|
S Phase
|
Transcriptional Regulation of White Adipocyte Differentiation
|
Meiotic Recombination
|
Retinoblastoma (RB) in Cancer
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Prostate Cancer
|
Signaling Pathways in Glioblastoma
|
TSH signaling pathway
|
Integrated Breast Cancer Pathway
|
Integrated Cancer pathway
|
Mitotic G1-G1/S phases
|
Cell Cycle
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
TGF beta Signaling Pathway
|
MAP kinase activation in TLR cascade
|
RAF/MAP kinase cascade
|
Mitotic Prophase
|
Mitotic Prometaphase
|
BMI1
|
ATM Signaling Pathway
|
Regulation of Microtubule Cytoskeleton
|
Mitotic G2-G2/M phases
|
APC/C-mediated degradation of cell cycle proteins
|
Cell Cycle Checkpoints
|
miRNA Regulation of DNA Damage ResponseWP45:G1 to S cell cycle control
|
Eukaryotic Transcription Initiation
|
Cardiac Hypertrophic Response
|
HIV Life Cycle
|
Nucleotide Excision Repair
|
RNA Polymerase II Transcription
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
mRNA Capping
|
MicroRNAs in cardiomyocyte hypertrophyWP707:DNA Damage Response
|
ID signaling pathway
|
DNA Replication
|
M/G1 Transition
|
Aryl Hydrocarbon Receptor
|
Oncostatin M Signaling Pathway
|
Synthesis of DNA
|
Regulation of DNA replication
|
Factors involved in megakaryocyte development and platelet production
|
miRNA Regulation of DNA Damage Response
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5707). |
---|
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018924) |
---|
REF 3 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. |